News | Artificial Intelligence | March 03, 2023

During the European Congress of Radiology, ECR2023, global medical imaging AI firm Oxipit announced that its diagnostic solutions will be available on the CARPL platform.

During the European Congress of Radiology, ECR2023, global medical imaging AI firm Oxipit announced that its diagnostic solutions will be available on the CARPL platform.

During the European Congress of Radiology, ECR2023, global medical imaging AI firm Oxipit announced that its diagnostic solutions will be available on the CARPL platform. Photo credit: Getty Images


March 3, 2023 — Oxipit, a creator of AI tools for global medical imaging, has announced that its diagnostic AI solutions will be available on the CARPL platform. CARPL platform users will have access to the full Oxipit AI product portfolio: ChestLink for healthy patient report automation, Quality for real-time quality assurance and ChestEye for preliminary reports. The move further builds on Oxipit strategy to increase global reach of company’s products, according to a statement released on the partnership. Both companies are participating at the European Congress of Radiology (ECR2023), held March 1-5 in Vienna, Austria.

CARPL connects AI developers and healthcare providers improving access, affordability and quality of medical care globally. The company explained it is an end-to-end technology platform for the testing, distribution and deployment of medical imaging AI in clinical practice. As such, CARPL bridges the gap between healthcare AI application providers and clinicians by being a one-stop solution to access, assess, and adopt AI solutions.

According to Gediminas Peksys, CEO of Lithuania-based Oxipit, “CARPL is our long-term partner for research and client deployments. It is a future savvy organization, quick to pick up the latest diagnostic innovations. With the CARPL platform, we may present our products within easy reach of a global medical audience.”

Dr. Vasanth Venugopal, Chief Medical Officer and Clinical Product Lead at CARPL.ai, said this of the partnership: “With the formalization of our partnership, strengthened by CARPL's capabilities to deploy AI solutions at scale across institutions and Oxipit's robust set of quality audit and autonomous solutions, we envision a future full of infinite possibilities to revolutionize radiology practice.” He further noted, “Oxipit’s CE approval for autonomous reporting of normal chest X-rays is a landmark achievement that “had forever changed the perception and potential of AI applications in radiology.”

The full Oxipit product portfolio will be offered on the CARPL platform, helping medical institutions to increase reporting efficiency, addressing radiologist shortages and improving diagnostic quality. The company summarized its AI solutions, noting:

ChestLink is the first autonomous AI application to receive a CE Class IIb certification. The application autonomously reports on chest X-rays featuring no abnormalities without any involvement from a radiologist. By autonomously reporting on healthy patient chest X-rays, ChestLink can automate 15-40% of daily reporting workflow depending on the type of medical institution.

Oxipit Quality acts as an AI-powered second-reader for diagnostic quality assurance. By analyzing medical images and corresponding radiologist reports, the application can detect diagnostic mistakes in real-time. If the platform detects an unreported finding, it instantly notifies the radiologist to take another look at the study. Oxipit Quality works with chest and MSK X-rays, MMG images and CT scans.

ChestEye is an AI-powered CAR application with support for 75 radiological findings. The application includes preliminary reporting and triage features. ChestEye serves as the first step for diagnostic AI adoption, with clients then being able to move automation or quality assurance depending on their usage scenario.  

More information:

https://oxipit.ai/ 

https://carpl.ai/

Related content:

Oxipit Introduces Quality Assurance for MSK, MG, and CT Modalities

Oxipit and AstraZeneca Join Forces to Aid Early Lung Cancer Detection


Related Content

News | Artificial Intelligence

July 22, 2024 — Healthcare artificial intelligence (AI) systems provider, Qure.ai, has announced its receipt of a Class ...

Time July 22, 2024
arrow
News | Radiology Business

July 19, 2024 — GE HealthCare announced it has entered into an agreement to acquire Intelligent Ultrasound Group PLC’s ...

Time July 19, 2024
arrow
News | Radiology Education

July 19, 2024 — Core tactics to address the current medical imaging and radiation therapy workforce shortage and build ...

Time July 19, 2024
arrow
News | Computed Tomography (CT)

July 18, 2024 — NeuroLogica Corp, a subsidiary of Samsung Electronics Co. Ltd., announced its latest configuration of ...

Time July 18, 2024
arrow
News | ASTRO

July 18, 2024 — The members of the American Society for Radiation Oncology (ASTRO) recently elected five new officers to ...

Time July 18, 2024
arrow
News | Digital Radiography (DR)

July 18, 2024 — At the Annual Meeting of AHRA (the Association for Medical Imaging Management), Agfa Radiology Solutions ...

Time July 18, 2024
arrow
News | Artificial Intelligence

July 17, 2024 — Hyperfine, a groundbreaking medical device company that has redefined brain imaging with the world’s ...

Time July 17, 2024
arrow
News | Magnetic Resonance Imaging (MRI)

July 16, 2024 — Fujifilm Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging ...

Time July 16, 2024
arrow
News | Radiology Business

July 15, 2024 — Vizient, Inc. announced a strategic partnership with leading carbon accounting platform provider Greenly ...

Time July 15, 2024
arrow
News | Computed Tomography (CT)

July 15, 2024 — NeuroLogica Corp, a subsidiary of Samsung Electronics Co. Ltd., announced its latest configuration of ...

Time July 15, 2024
arrow
Subscribe Now